“The Potential of Lagundi as a Supplemental Treatment for COVID-19 has gained Approval for Clinical Trial”

Lagundi as a Supplemental Treatment for COVID-19

By August 1, the Philippines will begin its clinical trials on Lagundi as an additional therapy for patients with coronavirus disease (COVID-19)

 The experiments have also been licensed by the University of the Philippines Scientific Ethics Board, according to the Science and Technology Secretary Fortunato Dela Peña.

 The aim of the study, which will begin on or before August 1 when the FDA clearance is released, is to show whether it is good to address the symptoms of COVID-19. He noted that like Tawa-Tawa, lagundi has anti-viral properties which makes it an acceptable option for COVID-19 patients to be handled symptomatically.

 This project looks forward to lagundi as an adjuvant treatment, where it may offer symptomatic relief without co-morbidities for the moderate Covid-19 patients. It also aims to assess whether lagundi will minimize the number of patients advancing from mild to moderate or serious cases.

 In view of this, Lagundi tablet or the syrup is a validated bronchodilator with its recorded indication for cough care, he said, adding nausea, cough, sore throat, myalgia, and exhaustion are the typical symptoms of Covid-19. Several reports have demonstrated the antipyretic, analgesic, anti-inflammatory and anti-viral effects of lagundi, too.

 Moreover, Lagundi is a proven cough treatment which is among the common COVID-19 symptoms. Science and Technology Department is still running experiments on the efficacy of pure coconut oil in recovered Covid-19 patients.

 Currently, there are 68,898 cases of COVID-19 nationwide including 23,072 recoveries and 1,835 deaths.

To know more about the Philippines News:

Leave a Reply

Your email address will not be published. Required fields are marked *